Interferon (IFN)-stimulated gene 15 (ISG15) is a ubiquitin-like molecule that conjugates to target proteins via a C-terminal LRLRGG motif and has antiviral function in vivo. We used structural modeling to predict human ISG15 (hISG15) residues important for interacting with its E1 enzyme, UbE1L. Kinetic analysis revealed that mutation of arginine 153 to alanine (R153A) ablated hISG15-hUbE1L binding and transthiolation of UbcH8. Mutation of other predicted UbE1L-interacting residues had minimal effects on the transfer of ISG15 from UbE1L to UbcH8. The capacity of hISG15 R153A to form protein conjugates in 293T cells was markedly diminished. Mutation of the homologous residue in mouse ISG15 (mISG15), arginine 151, to alanine (R151A) also attenuated protein ISGylation following transfection into 293T cells. We assessed the role of ISG15-UbE1L interactions in control of virus infection by constructing double subgenomic Sindbis viruses that expressed the mISG15 R151A mutant. While expression of mISG15 protected alpha/beta-IFN-receptor-deficient (IFN-␣␤R ؊/؊ ) mice from lethality following Sindbis virus infection, expression of mISG15 R151A conferred no survival benefit. The R151A mutation also attenuated ISG15's ability to decrease Sindbis virus replication in IFN-␣␤R ؊/؊ mice or prolong survival of ISG15 ؊/؊ mice. The importance of UbE1L was confirmed by demonstrating that mice lacking this ISG15 E1 enzyme were highly susceptible to Sindbis virus infection. Together, these data support a role for protein conjugation in the antiviral effects of ISG15.
A critical component of the innate immune response is the antiviral state induced by type I interferons (IFNs) (19, 46, 47) . In response to viral infection and the production of IFNs, cells alter their gene expression profiles to render themselves nonpermissive for viral infection and/or replication. PKR, RNase L, and Mx are well-characterized effectors in this response (40, 43) . However, experiments with mice that genetically lack one or all of these antiviral molecules clearly demonstrate that there are other important molecules induced by IFN (1, 48, 57, 58) . One such gene product, IFN-stimulated gene 15 (ISG15), was originally identified as a 15-kDa protein induced by IFN (2, 22) and subsequently as a 15-kDa protein that cross-reacts with antiubiquitin antibodies (13) . ISG15 resembles a diubiquitin molecule, with two domains each having significant homology to ubiquitin and other ubiquitin-like molecules (33) .
Analogously to ubiquitin, ISG15 is synthesized in a proform which is processed to reveal a C-terminal LRLRGG motif (41) . ISG15 conjugates to target proteins via an isopeptide bond using a series of IFN-induced enzymes: an E1-activating enzyme, UbE1L (53); E2-conjugating enzyme UbcH8/UbcM8 (20, 55) ; E3 ligase enzymes Herc5 (4, 49, 51) , HHARI (36) , and Efp (59) ; and a deconjugating enzyme, UBP43 (28) . Recent studies have confirmed that the activation of ISG15 by UbE1L is critical for protein ISGylation. Both UbE1L-deficient cells and UbE1L-deficient mice lack ISG15 conjugates following stimulation with IFN and lipopolysaccharide (21) .
Recent data from both in vivo and in vitro studies demonstrated that ISG15 has antiviral function. In vivo, the expression of ISG15 from a recombinant Sindbis virus protects alpha/ beta-IFN-receptor-deficient (IFN-␣␤R Ϫ/Ϫ ) (24), ISG15
Ϫ/Ϫ (25) , and CD1 (54) mice against lethality following Sindbis virus infection. In addition, ISG15-deficient mice display increased susceptibility to infection with Sindbis virus, herpes simplex virus type 1, gammaherpesvirus 68, and influenza A and B viruses (25) . In vitro, ISG15 induction correlates with IFN--mediated suppression of human immunodeficiency virus (HIV) replication, and ISG15 overexpression results in a decrease in cytoplasmic HIV transcripts and HIV protein synthesis (23) as well as decreased alphavirus replication (54) . Furthermore, ISG15 and UbE1L overexpression inhibits HIV replication and interferes with the ubiquitination of Tsg101 and Gag, which are required for HIV binding and release (34) . Together, these results have defined ISG15 as a critical IFNinduced antiviral molecule. ISG15's mechanism of antiviral action is not completely defined. The existence of an IFN-inducible pathway that mirrors ubiquitin conjugation has led to the hypothesis that protein ISGylation may be an important component of the IFN-induced innate immune response (12) . A role for protein conjugation in ISG15's antiviral function is suggested by the finding that heterologous expression of a conjugation-deficient form of ISG15 (LRLRAA) does not result in protection of IFN-␣␤R Ϫ/Ϫ (24) or ISG15 Ϫ/Ϫ (25) mice from lethality. Additional support for this hypothesis is that protein ISGylation is targeted by two viral immune evasion molecules. The NS1 protein of influenza B virus binds human ISG15 (hISG15) (52) and inhibits protein ISGylation (53) , while an ovarian tumor domain-containing protease found in nairoviruses and arteriviruses deconjugates ISGylated proteins and abrogates ISG15's protective antiviral function (9) .
Unconjugated ISG15 has also been demonstrated to have antiviral functions. In cell culture, overexpression of ISG15 can inhibit budding of Ebola virus VP40 viruslike particles (VLPs) by interacting with the Nedd4 ubiquitin ligase and inhibiting the ubiquitination of VP40 (29, 35) . Additionally, ISG15 has been found in the serum of volunteers treated with IFN-␤-serine (6) and mice infected with influenza virus (25) , suggesting that it may also function as a cytokine. Stimulation of human peripheral blood lymphocytes with ISG15 induces NK cell proliferation, augments lymphokine-activated killer activity, and stimulates IFN-␥ production (5, 42) but requires processing of pro-ISG15 to expose the two C-terminal glycine residues of ISG15's LRLRGG sequence (5) . ISG15 constitutively produced by a melanoma cell line induces human dendritic cell maturation (39) . Mouse ISG15 (mISG15) was reported as a neutrophil chemotactic factor during murine malarial infection with neutrophil-recruiting properties both in vitro and in vivo (38) . Thus, ISG15 likely has both conjugationdependent and conjugation-independent activities.
To further explore the role of protein ISGylation in ISG15's antiviral function, we analyzed the importance of the interaction of ISG15 with its E1 enzyme, UbE1L, in protein conjugation and in ISG15's antiviral function. By specifically targeting an interaction within the protein ISGylation pathway, we aspired to create a conjugation-deficient mutant of ISG15 which retains the C-terminal glycines in the LRLRGG sequence. We used structure-based mutagenesis to identify residues in hISG15 that are required for interaction with UbE1L and for conjugation of hISG15. Using these data, we mutagenized the homologous amino acid in mISG15 and analyzed the effect of these mutations on protein ISGylation and the antiviral effects of ISG15 in vivo. We found that mutation of hISG15 R153A mutations reduced hISG15-hUbE1L binding and disrupted protein ISGylation in 293T cells. Mutation of mISG15 R151A diminished both conjugation to target proteins and ISG15-mediated protection from Sindbis virus lethality in IFN-␣␤R Ϫ/Ϫ and ISG15 Ϫ/Ϫ mice. Additionally, mice lacking ISG15's E1 enzyme UbE1L had increased susceptibility to lethality following Sindbis virus infection. These data further support the conclusion that protein conjugation plays a critically important role in the antiviral effects of ISG15 in vivo by demonstrating the importance of mISG15 Arg151 and UbE1L in innate immune control of Sindbis virus infection.
MATERIALS AND METHODS
Expression of wild-type and mutant hISG15. Recombinant hISG15N13Y/ C78S (hereafter referred to as hISG15), harboring an Asn13-to-Tyr mutation in the amino-terminal ␤-grasp domain to provide a solvent-accessible site for radioiodination and a Cys78-to-Ser mutation to stabilize the resulting protein, was expressed in Escherichia coli AR58 cells. Cells harboring pGEX-ISG15N13Y/ C78S are an adaptation of earlier methods (33) . Expression in AR58 precluded the requirement for an arginine capping residue to prevent inactivation of the recombinant glutathione S-transferase (GST)-hISG15 by the periplasmic carboxypeptidase noted previously (32, 33) . Mutant hISG15 proteins were generated by the overlap extension PCR method using pGEX-hISG15N13Y/C78S as a template (17) . The GST-hISG15 proteins were isolated by glutathione-Sepharose chromatography, processed with thrombin, and purified to apparent homogeneity by Mono Q fast protein liquid chromatography (33) . Protein was quantified spectrophotometrically using an empirical 280-nm extinction coefficient of 0.885 ml/mg (33) . A portion of the recombinant proteins was radioiodinated by the chloramine T procedure to yield a specific radioactivity typically in the range of 3 ϫ 10 4 to 5 ϫ 10 4 cpm/pmol (32, 33) . Expression of hUbE1L and UbcH8. Recombinant human GST-UbE1L (herein referred to as hUbE1L) was expressed in Sf9 cells harboring pFASTBacHsUbE1L and purified to apparent homogeneity by glutathione-Sepharose chromatography. Active hUbE1L was quantified by its stoichiometric formation of 125 I-ISG15 thiolester (33) . Human UbcH8 was expressed by IPTG (isopropyl-␤-D-thiogalactopyranoside) induction of E. coli BL21(DE3) harboring pGEXHsUbcH8. GST-UbcH8 was isolated by glutathione-Sepharose chromatography, processed with thrombin, and purified to apparent homogeneity by Mono Q fast protein liquid chromatography (45) . Active UbcH8 was quantified by the stoichiometric formation of 125 I-ISG15 thiolester (14) .
Transthiolation kinetic assays. The effect of additional point mutations within hISG15N13Y/C78S was quantified kinetically by monitoring the initial rates of UbcH8-125 I-ISG15 thiolester formation under conditions identical to those used for 125 I-ubiquitin transthiolation by hUba1 (45) . Incubation mixtures of 25-l final volume contained 50 mM Tris-HCl (pH 7.5), 2 mM ATP, 10 mM MgCl 2 , 1 mM dithiothreitol, 22 nM hUbE1L, 500 nM UbcH8, and various concentrations of the 125 I-hISG15 mutant. Reaction mixtures were incubated for 2 min at 37°C under initial velocity conditions and quenched by the addition of 25 l of sodium dodecyl sulfate sample buffer without ␤-mercaptoethanol. The UbcH8-125 IhISG15 thiolester was resolved from free 125 I-hISG15 by sodium dodecyl sulfatepolyacrylamide gel electrophoresis. Gels were dried and autoradiographed, and UbcH8 thiolester was quantified by excising the bands from the gel and ␥ counting. The absolute amount of thiolester was calculated using the specific radioactivity of the 125 I-hISG15 (14, 45) . Kinetic constants were determined by nonlinear regression analysis (45) .
Eukaryotic ISG15 expression constructs. pGEX-hISG15N13Y/C78S and mutant hISG15 constructs were digested with BamHI and XhoI. Inserts were gel purified and subcloned into BamHI and XhoI sites in pcDNA4HisMaxC (Invitrogen). The N13Y and C78S mutations were reverted to wild type in pcDNA4HisMaxC-hISG15 constructs using the QuikChange Multi site-directed mutagenesis kit (Stratagene, La Jolla, CA). Nucleotides 1 to 465 of mISG15 were PCR amplified, adding a 5Ј HindIII site and a 3Ј KpnI site to facilitate subcloning into pCDNA3.1(ϩ) (Invitrogen, Carlsbad, CA). Using a QuikChange kit (Stratagene), site-directed mutagenesis was performed on mISG15 nucleotides 451 to 453, CGC (Arg) to GCC (Ala), to generate mouse ISG15 mutant mISG15 R151A. All insert sequences were confirmed by sequencing.
Cell culture and transfection. 293T, BHK-21, and ISG15 Ϫ/Ϫ murine embryonic fibroblasts (MEFs) were cultured in D10, consisting of Dulbecco modified Eagle medium (Cellgro; Mediatech, Herndon, VA) supplemented with 10% low-endotoxin fetal bovine serum (HyClone, Logan, UT), 100 U/ml penicillin, 100 g/ml streptomycin, 10 mM HEPES, 1 mM sodium pyruvate, and 2 mM L-glutamine (Biosource, Camarillo, CA). pCAGGS.MCS and eukaryotic expression plasmids encoding hUbE1L, UbcM8, and UbcH8 were kindly provided by Dong-Er Zhang (20) . Herc5 was kindly provided by Motoaki Ohtsubo (Kurume University, Fukuoka-ken, Japan). mUbE1L was PCR amplified from an IFN-␤-induced bone marrow macrophage cDNA library (20) and subcloned into pCRBlunt (Invitrogen). PCR amplification with a 5Ј primer containing an EcoRI site and a hemagglutinin tag and a 3Ј primer containing an XhoI site generated a product that was cloned into pCAGGS.MCS. 293T cells were transfected as described previously (20) and harvested 36 h (hISG15) or 24 and 36 h (mISG15) posttransfection. Each transfection experiment was performed a minimum of three times. ISG15
Ϫ/Ϫ MEFs were transfected using the Amaxa (Gaithersburg, MD) nucleofection system. MEFs (2 ϫ 10 6 ) were resuspended in 100 l buffer T and transferred to a cuvette containing either 10 g pCAGGS-green fluorescent protein (GFP) or 1 g pCAGGS-GFP with 9 g mISG15 or mISG15 R151A in equal volumes. Cells were transfected using program T-20 and recovered by addition of prewarmed D10. Each transfection was plated in one well of a six-well plate, and 18 to 24 h after transfection, cells were treated with 100 U/ml IFN-␤ (PBL Biomedical, Piscataway, NJ) for 36 h.
Western blotting. Cells were lysed on ice in equal volumes of Laemmli sample buffer containing protease inhibitor cocktail III (Sigma). Samples were boiled for 10 min, and equal volumes were separated on a 4 to 20% gradient gel (Bio-Rad, Hercules, CA) and transferred to polyvinylidene difluoride (GE Health Sciences, Piscataway, NJ). mISG15 and mISG15 conjugates were detected using anti-VOL. 83, 2009 ANTIVIRAL FUNCTION OF ISG15 Arg151 AND UbE1L 1603 mISG15 antibodies 2D12 and 3C2 as previously described (24) . Six-His-hISG15 was detected using a 1:3,000 dilution of a mouse monoclonal anti-His antibody (GE Healthcare). Rabbit polyclonal anti-Sindbis virus was a kind gift from Dianne Griffin (Johns Hopkins University, Baltimore, MD) (26) and was used at a 1:20,000 dilution. For loading controls, antivalosin-containing protein clone H-120 (Santa Cruz Biotechnology, Santa Cruz, CA) and anti-␤-actin monoclonal antibody clone SC-74 (Sigma, St. Louis, MO) were used at 1:500 and 1:3,000 dilutions, respectively. Polyclonal rabbit immunoglobulin fraction anti-GFP (Molecular Probes/Invitrogen) was diluted 1:1,000. Horseradish peroxidase-conjugated secondary antibodies were diluted 1:5,000 (Jackson ImmunoResearch, West Grove, PA), and blots were developed using ECL Plus (GE Health Sciences). To quantify mISG15 conjugate levels, blots were scanned on a Storm Phosphoimager (GE Healthcare) and analyzed using ImageQuant 5.2 (GE Healthcare). Transfection efficiency was normalized by dividing mISG15 conjugate volume by GFP volume within each sample. In each experiment, the ratio of mISG15 conjugates to GFP for mISG15 LRLRGG was arbitrarily set to 10 to allow comparison across four experiments. Generation and characterization of recombinant Sindbis viruses. Double subgenomic Sindbis virus dsTE12Q was generated from a cDNA clone by in vitro transcription and RNA transfection of BHK-21 cells as previously described (15, 24) . A Sindbis virus expressing mISG15 R151A was generated by PCR amplifying pCDNA3.1 mISG15 R151A with primers that contained 5Ј and 3Ј BstEII restriction sites and subcloning it into dsTE12Q. Viral stocks were produced and their titers were determined on BHK-21 cells as previously described (24) . Viral ISG15 expression was assessed by Western blotting. BHK-21 cells were infected at a multiplicity of infection (MOI) of 20 with dsTE12Q-or mISG15-expressing viruses. Cells were harvested 18 h postinfection and Western blotted for mISG15 or Sindbis virus proteins. Growth curves were performed at an MOI of 5 as previously described (16) .
Mouse studies. IFN-␣␤R Ϫ/Ϫ mice on the 129/SV/Pas background were initially obtained from M. Aguet, Swiss Institute of Experimental Cancer Research (Epalinges, Switzerland) (7, 31) . UbE1L Ϫ/Ϫ (21) and ISG15 Ϫ/Ϫ mice and ISG15 ϩ/ϩ littermate controls (37) have been described previously. All mice were bred and maintained at Washington University School of Medicine in accordance with all federal and university guidelines. Eight-to 10-week-old male IFN-␣␤R Ϫ/Ϫ mice were infected subcutaneously (s.c.) in the left hind footpad with 5 ϫ 10 6 PFU of virus diluted in 50 l of Hanks' balanced salt solution. Mice were followed for lethality or sacrificed on day 3, 5, or 7 to assess viral titer. Titers were by determined by plaque assay on BHK cells (24) . The limit of detection of the assay is 50 PFU for all organs. Four-day-old ISG15 Ϫ/Ϫ mice, ISG15
ϩ/ϩ littermates, UbE1L Ϫ/Ϫ mice, or C57/BL6 pups were infected in the right cerebral hemisphere with 1,000 PFU of virus in 10 l of Hanks' balanced salt solution and followed for lethality. To control for nutritional status and pup health, all litters contained six to eight pups with an average weight per pup of 2.1 g to 2.5 g.
Statistical analyses. All data were analyzed with Prism software (GraphPad, San Diego, CA). Growth curves were analyzed using one-way analysis of variance. Survival data were analyzed by the log-rank (Mantel-Cox) test, with death as the primary variable. Acute titer data were analyzed using the Mann-Whitney test.
RESULTS

Generation and kinetic characterization of hISG15 point mutants.
To examine the interactions of ISG15 with UbE1L, we mutated ISG15 residues predicted to interact with UbE1L. Narasimhan et al. have previously used the 3.0-Å crystal structure for Nedd8 bound to its AppBp1Uba3 heterodimeric activating enzyme as a structural model for hISG15 bound to hUbE1L (33) . This simulation identified six residues as putative binding "hot spots" for interaction of hISG15 with its activating E1 enzyme (Table 1) . Among these residues, several positions are not conserved with ubiquitin, providing potential residues that might contribute to the specificity of UbE1L for ISG15 rather than ubiquitin (33) .
In order to assess these positions as potential binding residues for hISG15 interaction with UbE1L, we expressed and purified hISG15 mutant proteins and performed functional binding assays by measuring the kinetics of UbE1L-catalyzed transfer (transthiolation) of ISG15 to UbcH8. Previous studies with the ubiquitin-and Nedd8 E1-activating enzymes (3, 45) (8, 56) .
When initial rates of UbE1L-catalyzed UbcH8 transthiolation were measured at different concentrations of 125 I-hISG15, the data followed hyperbolic kinetics, evidenced by the linearity of double reciprocal plots. Nonlinear regression analysis was used to calculate K m (previously shown to be equivalent to (3), indicating that the relative affinity of these ubiquitin-like proteins for their cognate activating enzymes is conserved across paralogs. Interestingly, the k cat for transthiolation of (2.6 Ϯ 0.1) ϫ 10 Ϫ2 s Ϫ1 is Ͼ100-fold lower than the values of 4.5 s Ϫ1 for Uba1 and 3.5 s Ϫ1 for AppBp1Uba3 (3, 45) . Most of the amino acid candidates identified within the carboxyl-terminal domain of hISG15 (Table 1) show modest increases in K m when mutated to alanine, corresponding to ⌬⌬G binding of ca. 1 kcal, suggesting that binding is distributed over the surface of the domain. The largest effects occur on mutation of either Glu132 or Arg153 to alanine ( Table 1) . Mutation of the former residue results in a sevenfold increase in K m and a fourfold decrease in k cat , leading to an overall decrease in catalytic specificity (defined as k cat /K m ) of 30-fold. Mutation of Arg153 to alanine (R153A) increases the K m significantly so that the initial rate becomes linear with respect to [hISG15] o (data not shown), preventing estimation of both K m and k cat . We estimated k cat /K m from the linear slope of v o versus [hISG15] o , the result of which revealed that the catalytic specificity is decreased Ͼ700-fold to Յ86 M Ϫ1 s Ϫ1 . Therefore, mutation of R153A effectively inactivates hISG15 with respect to UbE1L-catalyzed activation and subsequent conjugation. Significantly, Arg153 is paralogous to Arg72 of ubiquitin, a position critical in allowing cognate activating enzymes to distinguish among ubiquitin, Nedd8, and Sumo (3, 27, 50) .
Mutation of UbE1L-interacting residues affects ISG15 conjugation in vivo. To assess the effect of mutating UbE1L-interacting residues on hISG15 conjugation in vivo, we utilized a 293T transfection system to coexpress hISG15, hUbE1L, UbcH8, and Herc5. Mutation of hISG15 R153A confirmed that this residue was important for conjugation of hISG15 (Fig. 1A). As expected, wild-type hISG15 formed a characteristic ladder of protein conjugates when cotransfected with hUbE1L, UbcH8, and Herc5 (Fig. 1A) . In contrast, mutation of the hUbE1L-interacting residue R153A impaired the formation of ISG15 conjugates (Fig. 1A) , consistent with results observed during in vitro UbcH8 transthiolation reactions (Table 1) . Generation and conjugation of mISG15 R151A mutant. We next sought to determine the role of the UbE1L-interacting residue arginine 153 in the antiviral effects of ISG15. We have previously utilized a recombinant Sindbis virus system expressing mISG15 to demonstrate and study the antiviral activity of ISG15 (24, 25) . In order to determine the importance of the ISG15/UbE1L interaction for the antiviral activity of ISG15 in vitro and in a mouse infection model, we chose to generate a mutant mISG15 construct homologous to the hISG15 R153A mutation. Alignment of hISG15 and mISG15 sequences suggested that mISG15 arginine 151 was analogous to hISG15 arginine 153, a critical UbE1L-interacting residue in hISG15 (Fig. 1B) . Modeling the mISG15 structure by threading its sequence onto the hISG15 crystal structure confirmed that mISG15 Arg151 was structurally analogous to hISG15 Arg153 (data not shown). The mISG15 R151A mutant was stably expressed, as both polyclonal and monoclonal anti-mISG15 antibodies were able to detect mISG15 R151A (Fig. 1C and data  not shown) .
We tested the biological effect of those mutations on ISGylation of target proteins by cotransfecting constructs with mUbE1L and UbcM8. Wild-type mISG15 conjugated to cellular proteins, while a mutant form of ISG15 where the Cterminal glycines residues have been replaced with alanines (mISG15 LRLRAA) failed to form higher-molecular-weight conjugates as previously reported (24) (Fig. 1C) . UbE1L-interacting mutant mISG15 R151A was impaired in its ability to form conjugates, with no conjugates being detected following mISG15 R151A expression (Fig. 1C) .
To examine the effect of an E3 ligase on mISG15 mutant conjugation, we cotransfected mISG15 constructs, mUbE1L and UbcM8, with human Herc5. A mouse homologue of Herc5 has not been identified (10, 18) , and Efp, the only other identified ISG15 E3 ligase, targets specific substrates and does not (Fig. 1D) . mISG15 LRLRAA remained unable to form conjugates, but surprisingly, a low level of mISG15 R151A conjugates were detected 36 h posttransfection (Fig. 1D) . Ubiquitin conjugation utilizes several conjugating enzymes and numerous ligating enzymes. While only one E2 and three E3 ISGylation enzymes have been identified, it possible that there are additional conjugating and ligating enzymes for ISG15. If these enzymes are also IFN induced, they may not be expressed during 293T cell transfection. To provide optimal conjugation conditions with a full complement of enzymes expressed at endogenous levels, we therefore transfected ISG15 Ϫ/Ϫ MEFs with mISG15, mISG15 LRLRAA, or mISG15 R151A and treated transfected cells with IFN-␤. Similar to results obtained following 293T transfection, mutation of UbE1L-interacting residues impaired protein ISGylation in ISG15 Ϫ/Ϫ MEFs (Fig. 1E ). Both mISG15 LRLRAA and mISG15 R151A were severely compromised in their ability to form protein conjugates (Fig. 1E) . As IFN-␤-treated ISG15
Ϫ/Ϫ
MEFs should express all mouse IFN-induced conjugation enzymes, these data confirmed that both mISG15 LRLRAA and mISG15 R151A are severely compromised in their ability to conjugate to cellular proteins.
The mUbE1L-mISG15 interaction is important for mISG15's antiviral function. To assess the antiviral capability of mISG15 mutants, we constructed Sindbis viruses expressing mISG15, mISG15 LRLRAA, or mISG15 R151A (15) . The mISG15-containing viruses expressed similar levels of mISG15 or mISG15 mutant proteins (Fig. 2A, top panel) . All viruses expressed similar levels of Sindbis virus proteins ( Fig. 2A, bottom panel) and grew with equivalent kinetics to comparable final titers in BHK cells (Fig. 2B) .
Infection of IFN-␣␤R Ϫ/Ϫ mice with dsTE12Q, a doublesubgenomic strain of Sindbis virus, resulted in 100% lethality by day 7 postinfection (Fig. 2C) . As previously demonstrated (24) , expression of mISG15 LRLRGG protected mice from lethality (80% survival), while expression of mISG15 LR LRAA failed to protect IFN-␣␤R Ϫ/Ϫ mice from lethality (13% survival) (Fig. 2C) . Infection of mice with a Sindbis virus expressing mISG15 R151A resulted in a loss of protection from lethality, with only 17% of the mice surviving infection. The increase in lethality was consistent with the dramatic decrease in ISG15 conjugate formation (Fig. 1C to F) by the mISG15 R151A mutant. Additionally, the increased lethality was similar to the increase in lethality observed following infection with a virus expressing mISG15 LRLRAA, which lacks the C-ter- minal glycines required for ISG15 conjugation to cellular proteins (24) . The replication of dsTE12Q, a neurovirulent strain of Sindbis virus, is restricted to the brain and spinal cord in wild-type mice but is disseminated in mice lacking the type I IFN receptor (24) . Previous work has shown that while expression of mISG15 LRLRGG attenuated viral replication following infection, it alone did not restrict the dissemination of the virus (25) . To further evaluate the effect of the mISG15 R151A mutation on the antiviral activity of ISG15, we compared organ titers following infection with recombinant Sindbis viruses expressing mISG15 LRLRGG or mISG15 R151A. Viral spread was not restricted by mISG15 R151A, as viral titers were detected in multiple organs (Fig. 3) . Mutation of mISG15 R151A resulted in increased viral titers in brain, liver, spleen, and lungs (Fig. 3) of IFN-␣␤R Ϫ/Ϫ mice compared to the replication of a Sindbis virus containing mISG15 LRLRGG. These data show that mISG15 Arg151 strongly contributed to ISG15's antiviral function in IFN-␣␤R Ϫ/Ϫ mice.
Mutation of mISG15 Arg151 attenuates the antiviral function of ISG15 in Sindbis virus-infected ISG15
؊/؊ mice. To assess the ability of mISG15 R151A to rescue mice from lethality in the presence of an intact IFN response, ISG15 Ϫ/Ϫ mice were infected with Sindbis viruses expressing mISG15 LRLRGG, mISG15 LRLRAA, or mISG15 R151A. As previously published, ISG15
Ϫ/Ϫ pups display increased sensitivity to infection with dsTE12Q (25) . Heterologous expression of mISG15 LRLRGG, but not mISG15 LRLRAA, significantly increased the survival among infected ISG15 Ϫ/Ϫ pups (25) (Fig. 4) . Expression of mISG15 R151A results in a statistically significant attenuation of ISG15's antiviral effect (Fig. 4) , confirming that mISG15 Arg151 is important for ISG15's innate immune control of Sindbis virus infection. Interestingly, the survival curve of ISG15 Ϫ/Ϫ mice infected with viruses expressing mISG15 R151A is also statistically different from the survival curve of mice infected with viruses expressing mISG15 LRLRAA (Fig. 4) . These data indicated that mISG15 arginine 151 is critical for the antiviral effect of ISG15, but in the presence of an IFN response, this residue does not account for all of ISG15's antiviral activity. UbE1L-deficient mice (21) were infected with Sindbis virus strain dsTE12Q. Previous work has shown that cells isolated from UbE1L Ϫ/Ϫ mice express free ISG15 but are unable to form ISG15 conjugates (21) . Similarly, brain tissue from UbE1L Ϫ/Ϫ mice contains no detectable ISG15 conjugates 3 or 7 days post-dsTE12Q infection, while wild-type BL6 mice had ISG15 conjugates at both time points (Fig. 5A ). Following infection with dsTE12Q, UbE1L Ϫ/Ϫ mice display increased lethality compared to BL6 wild-type mice (Fig. 5B) . The increased lethality noted in UbE1L Ϫ/Ϫ mice is similar to the reported increased susceptibility of ISG15 Ϫ/Ϫ mice to dsTE12Q infection (25) and shows that UbE1L is important for innate control of Sindbis virus infection.
DISCUSSION
To investigate the importance of the ISG15-UbE1L binding in ISG15's antiviral function, we performed alanine mutagenesis on ISG15 amino acids predicted to interact with UbE1L. In vitro kinetic analysis of hISG15 mutants suggested that arginine 153 was a critical residue in the UbE1L-ISG15 interaction, while mutation of other predicted UbE1L-interacting residues in ISG15 had a more modest effect on binding (Table  1) . In cultured cells, mutation of hISG15 R153A greatly decreased protein ISGylation in a 293T cell conjugation system (Fig. 1A) , confirming the importance of ISG15-UbE1L binding for protein ISGylation.
To confirm that mutation of residues important for ISG15-UbE1L binding would disrupt ISG15's antiviral activity, we utilized a recombinant Sindbis virus system to express ISG15 in mice deficient in type I IFN signaling or ISG15 itself (24, 25) . As hISG15 has not been tested in this mouse system, we mutated the mISG15 residue analogous to hISG15 Arg153 (Fig.  1B) , allowing us to translate our kinetic analysis of the ISG15-UbE1L interaction into an in vivo antiviral function. Mutation of either hISG15 R153A or mISG15 R151A resulted in a significant diminution of protein ISGylation following transfection into 293T cells (Fig. 1) . Additionally, transfection of mISG15 R151A into IFN-␤-stimulated ISG15 Ϫ/Ϫ MEFs resulted in minimal protein ISGylation (Fig. 1E and F) . As all IFN-␤-induced conjugation enzymes should be expressed under these conditions, these data confirm that mutation of mISG15 151A significantly impacts protein ISGylation even under potentially optimal conjugation conditions.
As expected from prior studies, mISG15 LRLRGG forms abundant conjugates in a 293T transfection system, protects IFN-␣␤R Ϫ/Ϫ and ISG15 Ϫ/Ϫ mice from lethality, and results in decreased viral titers in infected IFN-␣␤R Ϫ/Ϫ mice (24) . Mutation of the terminal two glycines of mISG15 (mISG15 LRL RAA) abolishes protein conjugation and eliminates the capacity of ISG15 to protect from lethality during infection of IFN-␣␤R Ϫ/Ϫ and ISG15 Ϫ/Ϫ mice ( Fig. 1 and 2 ) (24, 25) . It has previously been shown that Sindbis viruses expressing mISG15 LRLRAA grow to higher titers than do viruses expressing mISG15 in IFN-␣␤R Ϫ/Ϫ mice (24).
Infection of IFN-␣␤R
Ϫ/Ϫ mice with Sindbis viruses expressing the mISG15 R151A mutation resulted in increased lethality and viral titer ( Fig. 2 and 3) . Additionally, mutation of mISG15 R151A resulted in increased lethality following infection of ISG15 Ϫ/Ϫ mice (Fig. 4) , confirming that this residue is important for ISG15-mediated control of Sindbis virus infection. Data from our kinetic analysis (Table 1) demonstrated that hISG15 Arg153, the residue analogous to mISG15 Arg151, is critical for ISG15-UbE1L binding and that mutation of either hISG15 Arg153 or mISG15 Arg151 drastically impairs protein ISGylation (Fig. 1 ). As such, we hypothesize that by mutating mISG15 Arg151, we are disrupting the ISG15-UbE1L interaction and interfering with the ISG15-mediated control of Sindbis virus infection. As the last four amino acids (LRGG) of ISG15 are disordered and not visualized in the ISG15 crystal structure (33) , it is unlikely that mutation of hISG15 R151/mISG15 R153 is inhibiting conjugation by altering the structure of the diglycine moiety. Additionally, we demonstrate that UbE1L is important for control of Sindbis virus infection, as mice deficient in UbE1L and protein ISGylation display increased sensitivity to Sindbis virus infection (Fig. 5) . These data are consistent with the hypothesis that ISG15-UbE1L binding, mISG15 Arg151, and protein ISGylation are important components of ISG15's antiviral function.
ISG15 has been proposed to have both conjugation-dependent and conjugation-independent antiviral functions. Interestingly, infection of ISG15 Ϫ/Ϫ mice with recombinant Sindbis viruses expressing mISG15 R151A resulted in a small, but statistically significant, increase in survival compared to that with expression of mISG15 LRLRAA (Fig. 4) , while infection of mice lacking type I IFN signaling showed no difference in survival from that of mice with type I IFN signaling (Fig. 2) . This suggests that, in a system which lacks only ISG15 but retains other IFN-induced genes, mISG15 R151A contributes an antiviral activity not found in mISG15 LRLRAA. In vivo conjugation in 293T cells and ISG15 Ϫ/Ϫ MEFs demonstrates that mISG15 R151A retains a small amount of residual conjugating activity (Fig. 1D and F) . One significant difference between ISG15
Ϫ/Ϫ and IFN-␣␤R Ϫ/Ϫ mice is the presence or absence of additional IFN-stimulated genes, including ISG15's E1, E2, and E3 enzymes. ISG15 mRNA expression can be induced in an IFN-␣␤-independent manner (11, 30, 44) . In contrast, ISG15
Ϫ/Ϫ mice should express all of the ISG15 conjugating machinery at levels approximating those in wild-type animals; in the presence of higher levels of conjugating enzymes in ISG15 Ϫ/Ϫ mice, any residual conjugating ability of mISG15 R151A could be amplified and result in increased survival. The increase in survival seen in ISG15 Ϫ/Ϫ mice suggests that the small number of residual conjugates formed by mISG15 R151A (Fig. 1) could have significant physiologic importance.
Alternatively, the difference in lethality could reflect additional, non-conjugation-dependent functions of mISG15 found in mISG15 R151A but not mISG15 LRLRAA. Recent data have demonstrated that intracellular expression of free ISG15 can inhibit budding of Ebola virus VP40 VLPs by interacting with the Nedd4 ubiquitin ligase and inhibiting the ubiquitination of VP40 (29, 35) . While expression of ISG15's conjugating enzymes was not required for the antiviral activity of ISG15 in these systems, the molecular determinants of ISG15 required were not determined. Additionally, it has previously been reported that the extracellular cytokine function of hISG15 requires exposure of the terminal two glycine residues (5). In our constructs, the terminal two diglycine residues are mutated in mISG15 LRLRAA but not mISG15 R151A (LALRGG).
We have demonstrated that mISG15 Arg151 is critical for protein conjugation and that mISG15 Arg151 and UbE1L play an important role in the control of Sindbis virus infection by ISG15. In the face of overwhelming immunocompromise in IFN-␣␤R Ϫ/Ϫ mice, protein ISGylation contributes the majority of ISG15's antiviral effect, with the contribution of a small amount of conjugates or an additional, conjugation-independent antiviral activity being minimal. These data confirm previous observations that conjugation-deficient forms of ISG15 are impaired in their antiviral activity and demonstrate that mISG15 Arg151 is a critical residue in ISG15's antiviral function.
